The specific free radical scavenger edaravone suppresses fibrosis in the bleomycin-induced and tight skin mouse models of systemic sclerosis

Arthritis and Rheumatism

Volumn 63, Issue 10, 2011, Pages 3086-3097

  Yoshizaki, Ayumi ^a   Yanaba, Koichi ^a   Ogawa, Asako ^a   Iwata, Yohei ^a   Ogawa, Fumihide ^a   Takenaka, Motoi ^a   Shimizu, Kazuhiro ^a   Asano, Yoshihide ^a   Kadono, Takafumi ^a   Sato, Shinichi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; COLLAGEN; DNA TOPOISOMERASE; HYDROGEN PEROXIDE; INTERLEUKIN 6; NITRIC OXIDE; NORPHENAZONE; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ARTICLE; AUTOIMMUNITY; CELL STIMULATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; FIBROBLAST; FIBROSIS; HYPERGAMMAGLOBULINEMIA; INFLAMMATORY CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SYSTEMIC SCLEROSIS;

ANIMALS; ANTIPYRINE; BLEOMYCIN; DISEASE MODELS, ANIMAL; FIBROSIS; FREE RADICAL SCAVENGERS; MICE; PULMONARY FIBROSIS; SCLERODERMA, SYSTEMIC; SKIN; TREATMENT OUTCOME;

EID: 80053495041     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.30470     Document Type: Article

References (49)

1. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15: 202-5. (Pubitemid 18073738)
2. Jinnin M,. Mechanisms of skin fibrosis in systemic sclerosis. J Dermatol 2010; 37: 11-25.
3. Okano Y,. Antinuclear antibody in systemic sclerosis (scleroderma). Rheum Dis Clin North Am 1996; 22: 709-35. (Pubitemid 26396047)
4. Sambo P, Baroni SS, Luchetti M, Paroncini P, Dusi S, Orlandini G, et al. Oxidative stress in scleroderma: maintenance of scleroderma fibroblast phenotype by the constitutive up-regulation of reactive oxygen species generation through the NADPH oxidase complex pathway. Arthritis Rheum 2001; 44: 2653-64. (Pubitemid 33049343)
5. Ogawa F, Shimizu K, Muroi E, Hara T, Hasegawa M, Takehara K, et al. Serum levels of 8-isoprostane, a marker of oxidative stress, are elevated in patients with systemic sclerosis. Rheumatology (Oxford) 2006; 45: 815-8. (Pubitemid 43985368)
6. Simonini G, Pignone A, Generini S, Falcini F, Cerinic MM,. Emerging potentials for an antioxidant therapy as a new approach to the treatment of systemic sclerosis. Toxicology 2000; 155: 1-15.
7. Abraham D, Distler O,. How does endothelial cell injury start? The role of endothelin in systemic sclerosis. Arthritis Res Ther 2007; 9 Suppl 2: S2.
8. Servettaz A, Goulvestre C, Kavian N, Nicco C, Guilpain P, Chereau C, et al. Selective oxidation of DNA topoisomerase 1 induces systemic sclerosis in the mouse. J Immunol 2009; 182: 5855-64.
9. Campo GM, Avenoso A, Campo S, D'Ascola A, Traina P, Sama D, et al. The antioxidant effect exerted by TGF-1β-stimulated hyaluronan production reduced NF-κB activation and apoptosis in human fibroblasts exposed to FeSo4 plus ascorbate. Mol Cell Biochem 2008; 311: 167-77.
10. Yamamoto T,. The bleomycin-induced scleroderma model: what have we learned for scleroderma pathogenesis? Arch Dermatol Res 2006; 297: 333-44. (Pubitemid 43144264)
11. Yoshizaki A, Iwata Y, Komura K, Ogawa F, Hara T, Muroi E, et al. CD19 regulates skin and lung fibrosis via Toll-like receptor signaling in a model of bleomycin-induced scleroderma. Am J Pathol 2008; 172: 1650-63. (Pubitemid 351793356)
12. Yoshizaki A, Yanaba K, Yoshizaki A, Iwata Y, Komura K, Ogawa F, et al. Treatment with rapamycin prevents fibrosis in tight-skin and bleomycin-induced mouse models of systemic sclerosis. Arthritis Rheum 2010; 62: 2476-87.
13. Akhmetshina A, Venalis P, Dees C, Busch N, Zwerina J, Schett G, et al. Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis. Arthritis Rheum 2009; 60: 219-24.
14. Inghilleri S, Morbini P, Oggionni T, Barni S, Fenoglio C,. In situ assessment of oxidant and nitrogenic stress in bleomycin pulmonary fibrosis. Histochem Cell Biol 2006; 125: 661-9. (Pubitemid 43785960)
15. Manoury B, Nenan S, Leclerc O, Guenon I, Boichot E, Planquois JM, et al. The absence of reactive oxygen species production protects mice against bleomycin-induced pulmonary fibrosis. Respir Res 2005; 6: 11.
16. Dooley A, Low SY, Holmes A, Kidane AG, Abraham DJ, Black CM, et al. Nitric oxide synthase expression and activity in the tight-skin mouse model of fibrosis. Rheumatology (Oxford) 2008; 47: 272-80. (Pubitemid 351267191)
17. Edaravone Acute Infarction Study Group. Effect of a novel free radical scavenger, edaravone (MCI-186), on acute brain infarction: randomized, placebo-controlled, double-blind study at multicenters. Cerebrovasc Dis 2003; 15: 222-9.
18. Yoshida H, Yanai H, Namiki Y, Fukatsu-Sasaki K, Furutani N, Tada N,. Neuroprotective effects of edaravone: a novel free radical scavenger in cerebrovascular injury. CNS Drug Rev 2006; 12: 9-20. (Pubitemid 44133577)
19. Asai T, Ohno Y, Minatoguchi S, Funaguchi N, Yuhgetsu H, Sawada M, et al. The specific free radical scavenger edaravone suppresses bleomycin-induced acute pulmonary injury in rabbits. Clin Exp Pharmacol Physiol 2007; 34: 22-6. (Pubitemid 46069581)
20. Zhang N, Komine-Kobayashi M, Tanaka R, Liu M, Mizuno Y, Urabe T,. Edaravone reduces early accumulation of oxidative products and sequential inflammatory responses after transient focal ischemia in mice brain. Stroke 2005; 36: 2220-5. (Pubitemid 41429250)
21. Hishida A,. Clinical analysis of 207 patients who developed renal disorders during or after treatment with edaravone reported during post-marketing surveillance. Clin Exp Nephrol 2007; 11: 292-6. (Pubitemid 350277612)
22. Ashcroft T, Simpson JM, Timbrell V,. Simple method of estimating severity of pulmonary fibrosis on a numerical scale. J Clin Pathol 1988; 41: 467-70. (Pubitemid 18098428)
23. Byrne SN, Limon-Flores AY, Ullrich SE,. Mast cell migration from the skin to the draining lymph nodes upon ultraviolet irradiation represents a key step in the induction of immune suppression. J Immunol 2008; 180: 4648-55.
24. Kawasaki T, Kitao T, Nakagawa K, Fujisaki H, Takegawa Y, Koda K, et al. Nitric oxide-induced apoptosis in cultured rat astrocytes: protection by edaravone, a radical scavenger. Glia 2007; 55: 1325-33. (Pubitemid 47328936)
25. Lacy P, Abdel-Latif D, Steward M, Musat-Marcu S, Man SF, Moqbel R,. Divergence of mechanisms regulating respiratory burst in blood and sputum eosinophils and neutrophils from atopic subjects. J Immunol 2003; 170: 2670-9. (Pubitemid 36245660)
26. Schnyder B, Pittet M, Durand J, Schnyder-Candrian S,. Rapid effects of glucose on the insulin signaling of endothelial NO generation and epithelial Na transport. Am J Physiol Endocrinol Metab 2002; 282: E87-94. (Pubitemid 34654111)
27. Yoshizaki A, Yanaba K, Iwata Y, Komura K, Ogawa A, Akiyama Y, et al. Cell adhesion molecules regulate fibrotic process via Th1/Th2/Th17 cell balance in a bleomycin-induced scleroderma model. J Immunol 2010; 185: 2502-15.
28. Ding J, Song D, Ye X, Liu SF,. A pivotal role of endothelial-specific NF-κB signaling in the pathogenesis of septic shock and septic vascular dysfunction. J Immunol 2009; 183: 4031-8.
29. Fujita M, Mizuta Y, Ikegame S, Ouchi H, Ye Q, Harada E, et al. Biphasic effects of free radical scavengers against bleomycin-induced pulmonary fibrosis. Pulm Pharmacol Ther 2008; 21: 805-11.
30. Tajima S, Bando M, Ishii Y, Hosono T, Yamasawa H, Ohno S, et al. Effects of edaravone, a free-radical scavenger, on bleomycin-induced lung injury in mice. Eur Respir J 2008; 32: 1337-43.
31. Jeannin P, Delneste Y, Lecoanet-Henchoz S, Gauchat JF, Life P, Holmes D, et al. Thiols decrease human interleukin (IL) 4 production and IL-4-induced immunoglobulin synthesis. J Exp Med 1995; 182: 1785-92.
32. Peterson JD, Herzenberg LA, Vasquez K, Waltenbaugh C,. Glutathione levels in antigen-presenting cells modulate Th1 versus Th2 response patterns. Proc Natl Acad Sci U S A 1998; 95: 3071-6. (Pubitemid 28135856)
33. Falanga V, Martin TA, Takagi H, Kirsner RS, Helfman T, Pardes J, et al. Low oxygen tension increases mRNA levels of α1 (I) procollagen in human dermal fibroblasts. J Cell Physiol 1993; 157: 408-12. (Pubitemid 23332786)
34. Parola M, Pinzani M, Casini A, Albano E, Poli G, Gentilini A, et al. Stimulation of lipid peroxidation or 4-hydroxynonenal treatment increases procollagen α1 (I) gene expression in human liver fat-storing cells. Biochem Biophys Res Commun 1993; 194: 1044-50. (Pubitemid 23254985)
35. Bellocq A, Azoulay E, Marullo S, Flahault A, Fouqueray B, Philippe C, et al. Reactive oxygen and nitrogen intermediates increase transforming growth factor-β1 release from human epithelial alveolar cells through two different mechanisms. Am J Respir Cell Mol Biol 1999; 21: 128-36. (Pubitemid 129508636)
36. Gabrielli A, Svegliati S, Moroncini G, Pomponio G, Santillo M, Avvedimento EV,. Oxidative stress and the pathogenesis of scleroderma: the Murrell's hypothesis revisited. Semin Immunopathol 2008; 30: 329-37.
37. Jiang D, Liang J, Fan J, Yu S, Chen S, Luo Y, et al. Regulation of lung injury and repair by Toll-like receptors and hyaluronan. Nat Med 2005; 11: 1173-9. (Pubitemid 43093664)
38. Ding AH, Nathan CF, Stuehr DJ,. Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages: comparison of activating cytokines and evidence for independent production. J Immunol 1988; 141: 2407-12.
39. Iharada A, Kaneko K, Tsuji S, Hasui M, Kanda S, Nishiyama T,. Increased nitric oxide production by T- and B-cells in idiopathic nephrotic syndrome. Pediatr Nephrol 2009; 24: 1033-8.
40. Kobayashi S, Imajoh-Ohmi S, Kuribayashi F, Nunoi H, Nakamura M, Kanegasaki S,. Characterization of the superoxide-generating system in human peripheral lymphocytes and lymphoid cell lines. J Biochem 1995; 117: 758-65.
41. Weihrauch D, Xu H, Shi Y, Wang J, Brien J, Jones DW, et al. Effects of D-4F on vasodilation, oxidative stress, angiostatin, myocardial inflammation, and angiogenic potential in tight-skin mice. Am J Physiol Heart Circ Physiol 2007; 293: H1432-41. (Pubitemid 47367186)
42. Marie I, Beny JL,. Endothelial dysfunction in murine model of systemic sclerosis: tight-skin mice 1. J Invest Dermatol 2002; 119: 1379-87. (Pubitemid 36005624)
43. Sato S, Fujimoto M, Hasegawa M, Takehara K,. Altered blood B lymphocyte homeostasis in systemic sclerosis: expanded naive B cells and diminished but activated memory B cells. Arthritis Rheum 2004; 50: 1918-27. (Pubitemid 38725103)
44. Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006; 354: 2655-66.
45. Marshak-Rothstein A,. Toll-like receptors in systemic autoimmune disease. Nat Rev Immunol 2006; 6: 823-35. (Pubitemid 44631651)
46. Yoshizaki A, Komura K, Iwata Y, Ogawa F, Hara T, Muroi E, et al. Clinical significance of serum HMGB-1 and sRAGE levels in systemic sclerosis: association with disease severity. J Clin Immunol 2009; 29: 180-9.
47. Yoshizaki A, Iwata Y, Komura K, Hara T, Ogawa F, Muroi E, et al. Clinical significance of serum hyaluronan levels in systemic sclerosis: association with disease severity. J Rheumatol 2008; 35: 1825-9.
48. Itano N, Kimata K,. Mammalian hyaluronan synthases. IUBMB Life 2002; 54: 195-9. (Pubitemid 36008328)
49. Campo GM, Avenoso A, Campo S, Angela D, Ferlazzo AM, Calatroni A,. TNF-α, IFN-γ, and IL-1β modulate hyaluronan synthase expression in human skin fibroblasts: synergistic effect by concomital treatment with FeSO4 plus ascorbate. Mol Cell Biochem 2006; 292: 169-78. (Pubitemid 44697411)